BlackRock Advisors’s Neurogene NGNE Stock Holding History

BlackRock Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$10.4M	Buy	31,412 +4,893	+18%	+$1.32M	0.01%	857
2016 Q3	$7.09M	Buy	26,519 +6,290	+31%	+$1.27M	0.01%	1010
2016 Q2	$2.68M	Buy	20,229 +414	+2%	+$65.8K	﹤0.01%	1332
2016 Q1	$3.5M	Buy	19,815 +4,455	+29%	+$866K	﹤0.01%	1228
2015 Q4	$3.83M	Sell	15,360 -5	-0%	-$1.32K	﹤0.01%	1184
2015 Q3	$4.32M	Buy	15,365 +9,595	+166%	+$2.21M	﹤0.01%	1135
2015 Q2	$801K	Hold	5,770	–	–	﹤0.01%	1827
2015 Q1	$949K	Buy	5,770 +80	+1%	+$16.3K	﹤0.01%	1595
2014 Q4	$854K	Sell	5,690 -20	-0.4%	-$2.85K	﹤0.01%	1592
2014 Q3	$761K	Sell	5,710 -540	-9%	-$82.3K	﹤0.01%	1627
2014 Q2	$1.18M	Sell	6,250 -10	-0.2%	-$1.93K	﹤0.01%	1399
2014 Q1	$1.59M	Buy	+6,260	New	+$1.61M	﹤0.01%	1270

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BlackRock Advisors's NGNE Position: Q4 2016 in Review

BlackRock Advisors increased its Neurogene (NGNE) stake by 18% in Q4 2016, buying an estimated $1.32M and bringing the position to 31,412 shares worth $10.4M. The position accounts for 0.01% of the portfolio, ranked #857.

BlackRock Advisors first reported a position in NGNE in Q1 2014 and has held it in 12 quarters since. 49 funds tracked by Wall St. Rank hold NGNE as of Q4 2016.

BlackRock Advisors held 31,412 shares of Neurogene worth $10.4M as of Q4 2016.
BlackRock Advisors bought 4,893 Neurogene shares in Q4 2016, an estimated $1.32M.
Neurogene made up 0.01% of BlackRock Advisors's portfolio in Q4 2016, its #857 holding.
BlackRock Advisors first reported a position in Neurogene in Q1 2014 and has held it in 12 quarters since.
49 funds tracked by Wall St. Rank held Neurogene as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.